介绍导致截肢的糖尿病足并发症引起全球健康关注。富血小板血浆(PRP)凝胶已成为一种有希望的溃疡愈合方法,利用自体PRP提供的生长因子来增强组织愈合。因此,我们旨在评估PRP治疗不愈合的糖尿病足溃疡的成功频率.方法拟实验研究,在拉合尔进行,巴基斯坦,从2021年4月至2022年10月,采用连续抽样技术,纳入80名符合条件的糖尿病足溃疡无应答患者.纳入标准涉及两种性别的患者,年龄45-75岁,糖尿病足溃疡未愈,和排除标准考虑因素,如在同一部位复发性溃疡,吸烟,和免疫抑制或抗凝药物治疗。基线人口统计详细信息,用量表测量溃疡,和AutoCAD(Autodesk、Inc.,旧金山,加州,记录了美国)辅助的溃疡基础定量。按照严格的无菌方案进行自体PRP注射,在四周内以指定的间隔进行敷料更换和评估。治疗成功,定义为四周后愈合>90%,是主要结果。数据分析利用IBMSPSSStatisticsforWindows,26.0版(2019年发布;IBMCorp.,Armonk,纽约,美国),在适当的情况下,采用分层后卡方检验和t检验进行显著差异。结果患者平均年龄为60.40±9.72岁,糖尿病的平均病程为9.48±2.21年,平均溃疡时间为11.41±1.63个月。治疗成功率为63.7%。年龄,性别,疾病持续时间对治疗成功率无显著影响。然而,BMI正常且溃疡持续时间较短的患者的成功率明显较高(分别为p<0.001和p=0.002).结论本研究重申了PRP治疗不愈合的糖尿病足溃疡的疗效。与以前的研究保持一致。尽管与文献报道相比成功率略低,PRP仍然是治疗糖尿病足溃疡的有前途的药物。
Introduction Diabetic foot complications leading to limb amputations pose a global health concern. Platelet-rich plasma (PRP) gel has emerged as a promising method for ulcer healing, leveraging the growth factors provided by autologous PRP to enhance tissue healing. Therefore, we aimed to assess the frequency of the success of PRP therapy in the treatment of non-healing diabetic foot ulcers. Methods This quasi-experimental study, conducted in Lahore, Pakistan, from April 2021 to October 2022, enrolled 80 eligible individuals with non-responsive diabetic foot ulcers using a consecutive sampling technique. Inclusion criteria involved patients of both genders, aged 45-75 years, with unhealed diabetic foot ulcers, and exclusion criteria considered factors such as recurrent ulcers at the same site, smoking, and immunosuppressive or anticoagulant drug therapy. Baseline demographic details, ulcer measurements using a scale, and AutoCAD (Autodesk, Inc., San Francisco, California, United States)-assisted quantification of ulcer base were recorded. Autologous PRP injections were administered following strict aseptic protocols, with dressing changes and assessments performed at specified intervals over four weeks. Treatment success, defined as >90% healing after four weeks, was the primary outcome. Data analysis utilized IBM SPSS Statistics for Windows, Version 26.0 (Released 2019; IBM Corp., Armonk, New York, United States), employing post-stratification chi-square and t-tests where appropriate for significant differences. Results The mean age of the patients was 60.40 ± 9.72 years, the mean duration of diabetes was 9.48 ± 2.21 years, and the mean ulcer duration was 11.41 ± 1.63 months. The treatment success rate was 63.7%. Age, gender, and disease duration showed no significant impact on treatment success. However, patients with a normal BMI and shorter ulcer duration exhibited a significantly higher success rate (p <0.001 and p = 0.002, respectively). Conclusions This study reaffirms the efficacy of PRP in treating non-healing diabetic foot ulcers, aligning with previous research. Despite a slightly lower success rate compared to literature reports, PRP remains a promising agent for managing diabetic foot ulcers.